Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Cancer Proteomics

Carl Borrebaeck's Biography

Carl Borrebaeck, Professor and Deputy Vice Chancellor, Lund University

Prof. Carl Borrebaeck is chairman of the Department of Immunotechnology, Lund University and program Director of the Strategic Center for Translational Cancer Research – CREATE Health ( He received the first chair as professor of Immunotechnology in Scandinavia 1989. His main research interests are cancer proteomics, for early detection and prognosis, and antibody engineering, for the generation of human therapeutic antibodies. He is a permanent member of the Royal Swedish Academy of Engineering Sciences and deputy vice chancellor of Lund University, with a special responsibility for its innovation system. He received the AKZO Nobel Science Award 2009, for his contributions to cancer proteomics and antibody-based therapy. Prof. Borrebaeck spent a sabbatical year at the Oklahoma Medical Research Foundation 1996-97 and did his post-doctoral training at the University of California in Davis. He received his Doctor of Science (D.Sc.) in 1979. His research has resulted in several spin-out companies, such as BioInvent International AB, Alligator Bioscience AB, Immunovia AB and SenzaGen AB.

Carl Borrebaeck Image

Serum Molecular Portraits – Solving the Puzzle of Cancer

Tuesday, 16 October 2012 at 09:30

Add to Calendar ▼2012-10-16 09:30:002012-10-16 10:30:00Europe/LondonSerum Molecular Portraits – Solving the Puzzle of Cancer

One of the driving forces in personalized medicine is the search for protein patterns that can be utilized for improved diagnosis, assessing the risk for tumor relapse and disease progression, as well as for evidence based therapy selection. We have designed and developed antibody microarray, a high-throughput technology for protein expression profiling, to the point where it is now generating data for improved diagnosis, patient stratification, risk assessment, as well as giving insights into disease biology. Several clinical studies have been performed, including analysis of serum/plasma/tissue proteomes from patients suffering from e.g. breast cancer, glioblastoma multiforme, pancreatic carcinoma, gastric adenocarcinoma, chronic lymphocytic leukemia, and Non-Hodgkin lymphomas. The presentation will be focusing on prognostication and risk classification of metastatic breast cancer.

Add to Calendar ▼2012-10-16 00:00:002012-10-17 00:00:00Europe/LondonCancer